# A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

> **NCT07672223** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 570 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** SYS6010
- **DRUG:** Enlonstobart
- **DRUG:** Tislelizumab
- **DRUG:** Toripalimab ±+platinum-based doublet chemotherapy
- **DRUG:** Durvalumab
- **DRUG:** Pembrolizumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT07672223
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-25
- **Primary completion:** 2029-09-30
- **Final completion:** 2031-11-30
- **Target enrollment:** 570 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07672223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07672223, "A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07672223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*